GLP-1 medicines are reshaping diabetes and weight-loss care, driving a race for customers, capital and market share. The SANOR GLP-1 Market Monitor tracks the companies, deals and commercial developments shaping this market.
Updated 23 September 2026
Annual global market size · 2025
Forecast annual growth (CAGR) · 2025–2035
Last 12 months
Last 12 months
Roche says its experimental weekly injection reduced weight and blood sugar in a mid-stage diabetes study. The results do not establish an advantage over rival medicines.
RocheFierce Pharma reports that newly released agreement documents have prompted questions about how much Lilly’s US pricing deal will save on GLP-1 obesity medicines.
Eli LillyNovo Nordisk says its experimental CagriSema injection produced more weight loss than a tested dose of Lilly’s tirzepatide in adults with type 2 diabetes. The comparison does not cover every available dose.
Lilly says construction has begun on a $6.5 billion Houston factory to make ingredients for Foundayo and other medicines. The factory is intended to expand production capacity; it is not yet operating.
Eli LillyLilly has stopped work on the experimental obesity drug LY4064912, Fierce Biotech reported. The decision concerns an early research project, rather than Lilly’s approved weight-loss medicines.
Eli LillyFierce Pharma reported record weekly prescriptions for Novo’s Wegovy pill and Lilly’s Foundayo. The figures track prescriptions, including refills, rather than new patients or comparative treatment results.
Revvity agreed to acquire Human Cell Design, adding human-relevant cell models used in diabetes, obesity and GLP-1 drug discovery. Financial terms were not disclosed.
RevvityRose Pharma will use MannKind’s inhalation technology to develop an inhaled version of an experimental weight-loss drug. MannKind receives a stake in Rose Pharma and a share of potential future sales.
MannKindInvestors led by BVF Partners are providing Superluminal with $60 million to advance an experimental obesity treatment. Lilly is participating as an investor in this funding round.
Gan & Lee developed bofanglutide; Menarini will seek approval and sell the medicine in 39 European countries if approved. Menarini will pay Gan & Lee €62 million initially for the exclusive rights.
Novo Nordisk has launched the daily tablet version of Wegovy in Germany, Reuters reported. The launch brings the weight-management medicine to its first European Union market in pill form.
Novo NordiskLilly reports one-year results from studies adding weight-loss drug Zepbound to Taltz, its treatment for psoriasis and psoriatic arthritis. The studies compared the combination with Taltz alone.
Eli LillyGrow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
